Effect of latanoprost on the expression of matrix metalloproteinases and tissue inhibitor of metalloproteinase 1 on the ocular surface

Archives of Ophthalmology

Volumn 128, Issue 4, 2010, Pages 466-471

  Honda, Norihiko ^a   Miyai, Takashi ^b   Nejima, Ryohei ^b   Miyata, Kazunori ^b   Mimura, Tatsuya ^a   Usui, Tomohiko ^a   Aihara, Makoto ^a   Araie, Makoto ^a   Amano, Shiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Miyata Eye Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EYE DROPS; GELATINASE B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERSTITIAL COLLAGENASE; LATANOPROST; MESSENGER RNA; PHOSPHATE BUFFERED SALINE; TIMOLOL; TIMOLOL MALEATE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONJUNCTIVA EPITHELIUM; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; EPITHELIUM CELL; EYE; FEMALE; GEL; GLAUCOMA; HUMAN; HUMAN CELL; LACRIMAL FLUID; MALE; MOUSE; NONHUMAN; NORMAL TENSION GLAUCOMA; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURFACE PROPERTY;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOTTING, WESTERN; CONJUNCTIVA; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; FEMALE; GLAUCOMA, OPEN-ANGLE; GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE (NADP+); HUMANS; IMMUNOHISTOCHEMISTRY; INTRAOCULAR PRESSURE; LOW TENSION GLAUCOMA; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 9; MICE; MIDDLE AGED; PROSTAGLANDINS F, SYNTHETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TEARS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 77950853336     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.40     Document Type: Article

References (19)

1. Lindsey JD, Kashiwagi K, Boyle D, Kashiwagi F, Firestein GS, Weinreb RN. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res. 1996;15(8):869-875. (Pubitemid 26305802)
2. Weinreb RN, Kashiwagi K, Kashiwagi F, Tsukahara S, Lindsey JD. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997;38(13):2772-2780. (Pubitemid 28009399)
3. Sivak JM, Fini ME. MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. Prog Retin Eye Res. 2002;21(1):1-14.
4. Wu KY, Wang HZ, Hong SJ. Effect of latanoprost on cultured porcine corneal stromal cells. Curr Eye Res. 2005;30(10):871-879. (Pubitemid 43154705)
5. Mietz H, Esser JM, Welsandt G, et al. Latanoprost stimulates secretion of matrix metalloproteinases in tenon fibroblasts both in vitro and in vivo. Invest Ophthalmol Vis Sci. 2003;44(12):5182-5188. (Pubitemid 37475387)
6. Oh DJ, Martin JL, Williams AJ, et al. Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost. Invest Ophthalmol Vis Sci. 2006;47(3):953-963. (Pubitemid 46768327)
7. Wang N, Lindsey JD, Angert M, Weinreb RN. Latanoprost and matrix metalloproteinase-1 in human choroid organ cultures. Curr Eye Res. 2001;22(3):198-207. (Pubitemid 32881425)
8. Oh DJ, Martin JL, Williams AJ, Russell P, Birk DE, Rhee DJ. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2006;47(9):3887-3895. (Pubitemid 46044304)
9. Ota T, Murata H, Sugimoto E, Aihara M, Araie M. Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation. Invest Ophthalmol Vis Sci. 2005; 46(6):2006-2011.
10. Mishima S, Gasset A, Klyce SD Jr, Baum JL. Determination of tear volume and tear flow. Invest Ophthalmol. 1966;5(3):264-276.
11. Sen E, Nalcacioglu P, Yazici A, et al. Comparison of the effects of latanoprost and bimatoprost on central corneal thickness. J Glaucoma. 2008;17(5):398-402.
12. Lass JH, Eriksson GL, Osterling L, Simpson CV; Latanoprost Corneal Effects Study Group. Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: a double-masked, randomized, one-year study. Ophthalmology. 2001;108(2):264-271. (Pubitemid 32115954)
13. Fini ME, Yue BY, Sugar J. Collagenolytic/gelatinolytic metalloproteinases in normal and keratoconus corneas. Curr Eye Res. 1992;11(9):849-862.
14. Kenney MC, Chwa M, Opbroek AJ, Brown DJ. Increased gelatinolytic activity in keratoconus keratocyte cultures: a correlation to an altered matrix metalloproteinase-2/tissue inhibitor of metalloproteinase ratio. Cornea. 1994;13(2):114-124. (Pubitemid 24083047)
15. Zhou L, Sawaguchi S, Twining SS, Sugar J, Feder RS, Yue BY. Expression of degradative enzymes and protease inhibitors in corneas with keratoconus. Invest Ophthalmol Vis Sci. 1998;39(7):1117-1124. (Pubitemid 28247345)
16. Lema I, Durán JA. Inflammatory molecules in the tears of patients with keratoconus. Ophthalmology. 2005;112(4):654-659. (Pubitemid 41108867)
17. Smith VA, Hoh HB, Easty DL. Role of ocular matrix metalloproteinases in peripheral ulcerative keratitis. Br J Ophthalmol. 1999;83(12):1376-1383.
18. Sakimoto T, Shoji J, Sawa M. Active form of gelatinases in tear fluid in patients with corneal ulcer or ocular burn. Jpn J Ophthalmol. 2003;47(5):423-426. (Pubitemid 37102819)
19. Amano S, Nakai Y, Ko A, Inoue K, Wakakura M. A case of keratoconus progression associated with the use of topical latanoprost. Jpn J Ophthalmol. 2008; 52(4):334-336.